<?xml version="1.0" encoding="UTF-8"?>
<p>Of note, anti‐TNF therapy has been employed in the management of severe sepsis, with a meta‐analysis demonstrating reduced overall mortality when used in severe sepsis before shock, and improved survival at 30 days in patients with shock or high baseline levels of IL‐6.
 <xref rid="apt15779-bib-0078" ref-type="ref">
  <sup>78</sup>
 </xref> There are no data on the incidence and severity of SARS or COVID‐19 in patients on anti‐TNF medications. Anti‐TNF agents were utilised in the initial phase of the SARs epidemic, although the overall evidence for efficacy is lacking.
 <xref rid="apt15779-bib-0079" ref-type="ref">
  <sup>79</sup>
 </xref>
</p>
